NCT03891706 is a Phase 1 clinical trial of tumor-specific TCR-T cells in Solid Tumor, sponsored by Guangzhou FineImmune Biotechnology Co., LTD..

Who is sponsoring NCT03891706?

NCT03891706 is sponsored by Guangzhou FineImmune Biotechnology Co., LTD..

What drugs are being tested in NCT03891706?

Interventions in NCT03891706: tumor-specific TCR-T cells, Interleukin-2.

What condition does NCT03891706 study?

NCT03891706 studies Solid Tumor.

Is NCT03891706 still recruiting?

NCT03891706 is currently recruiting now. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT03891706

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

Recruiting now Phase 1 Last updated 19 September 2024

What this trial tests

Phase 1 trial testing tumor-specific TCR-T cells in Solid Tumor in 30 participants. Currently enrolling.

Timeline

8 January 2019

Primary endpoint
1 October 2025

31 December 2025

Quick facts

Lead sponsor	Guangzhou FineImmune Biotechnology Co., LTD.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	8 January 2019
Primary completion	1 October 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

tumor-specific TCR-T cells — full drug profile →
Interleukin-2

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Guangzhou FineImmune Biotechnology Co., LTD. — full company profile →

Who can join

Adults 18 to 70, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor . The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q, Li J, Zheng H, Yang S, et al · · 2023 · cited 102× · PMID 36750830 · DOI 10.1186/s12943-023-01735-9
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q, Jiang Y, Xiang S, Kaboli PJ, et al · · 2021 · cited 97× · PMID 33859650 · DOI 10.3389/fimmu.2021.658753
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
Li J, Xiao Z, Wang D, Jia L, et al · · 2023 · cited 52× · PMID 37649123 · DOI 10.1186/s12943-023-01844-5
T Cell Based Immunotherapy for Cancer: Approaches and Strategies.
Want MY, Bashir Z, Najar RA. · · 2023 · cited 44× · PMID 37112747 · DOI 10.3390/vaccines11040835
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges.
Pang Z, Lu MM, Zhang Y, Gao Y, et al · · 2023 · cited 41× · PMID 38037114 · DOI 10.1186/s40364-023-00534-0
Breaking Bottlenecks for the TCR Therapy of Cancer.
Gaissmaier L, Elshiaty M, Christopoulos P. · · 2020 · cited 40× · PMID 32937956 · DOI 10.3390/cells9092095
T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.
Crowther MD, Svane IM, Met Ö, Met Ö. · · 2020 · cited 17× · PMID 32630096 · DOI 10.3390/cells9071588
Adoptive cell therapies in thoracic malignancies.
Lasvergnas J, Naigeon M, Chouahnia K, Zelek L, et al · · 2022 · cited 10× · PMID 35129636 · DOI 10.1007/s00262-022-03142-3

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Guangzhou FineImmune Biotechnology Co., LTD. trials

Trials by the same sponsor.

NCT07493044 — An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
NCT06942143 — An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06716619 — A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors · Phase 1 · recruiting
NCT06302062 — Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03891706 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou FineImmune Biotechnology Co., LTD.
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03891706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing